Assess applications and Assess applications and Assess applications and Assess applications and implement if endorsed implement if endorsed implement if endorsed implement if endorsed funding of new products funding of new funding of new funding of new and services and changes products and services products and services products and services to existing products and and changes to existing and changes to existing and changes to existing services for the Australian products and services products and services products and services blood sector in for the Australian blood for the Australian blood for the Australian blood accordance with Schedule sector in accordance sector in accordance sector in accordance 4 of the National Blood with Schedule 4 of the with Schedule 4 of the with Schedule 4 of the Agreement National Blood National Blood National Blood Agreement Agreement Agreement Immunoglobulin Monitor and improve Monitor and improve Monitor and improve Monitor and improve distribution and inventory distribution and distribution and distribution and Governance arrangements for Ig inventory arrangements inventory arrangements inventory arrangements products for Ig products for Ig products for Ig products KEY PERFORMANCE INDICATORS products are available to meet clinical need. Collection and production yield for domestic immunoglobulin maximised. Discards as a percentage of net issues of red blood cells less than 2.5%. Variance between actual and NBA estimated demand for supply of products is less than 5%.
Assess applications and implement if endorsed funding of new products and services and changes to existing products and services for the Australian blood sector in accordance with Schedule 4 of the National Blood Agreement Assess applications and implement if endorsed funding of new products and services and changes to existing products and services for the Australian blood sector in accordance with Schedule 4 of the National Blood Agreement Assess applications and implement if endorsed funding of new products and services and changes to existing products and services for the Australian blood sector in accordance with Schedule 4 of the National Blood Agreement Assess applications and implement if endorsed funding of new products and services and changes to existing products and services for the Australian blood sector in accordance with Schedule 4 of the National Blood Agreement Immunoglobulin Governance Monitor and improve distribution and inventory arrangements for Ig products Monitor and improve distribution and inventory arrangements for Ig products Monitor and improve distribution and inventory arrangements for Ig products Monitor and improve distribution and inventory arrangements for Ig products KEY PERFORMANCE INDICATORS products are available to meet clinical need. Collection and production yield for domestic immunoglobulin maximised. Discards as a percentage of net issues of red blood cells less than 2.5%. Variance between actual and NBA estimated demand for supply of products is less than 5%.
2018-19-NBA-Corporate-Plan-Web_08102018.docx